Ferrero J M - Centre Antoine Lacassagne, Nice, France.

基本信息

浏览量：43

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 83 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

131P Efficacy of neoadjuvant letrozole and palbociclib in HER2-low vs HER2 zero luminal breast cancer: An analysis of the Unicancer Neopal phase II study

Jean-Sébastien Frenel,Anne Vincent‐Salomon,Jérôme Lemonnier,Véronique D’Hondt,Isabelle Desmoulins,Pierre Heudel,François P. Duhoux, George Emile, M.A. Mouret Reynier,Florence Dalenc,Christelle Jouannaud,Laurence Vénat-Bouvet,

ESMO Openno. 1 (2023): 101470-101470

引用0浏览0引用

Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAFV600-mutated melanoma

J. Y. Blay,C. Cropet,S. Mansard,Y. Loriot,C. De La Fouchardiere,J. Haroche, D. Topart,D. Tougeron,B. You,A. Italiano,V. Le Brun-Ly,J. M. Ferrero,

ESMO OPENno. 6 (2023): 102038-102038

引用0浏览0WOS引用

217P Incidence and outcome of brain and/or leptomeningeal metastatic disease in HER2-low breast cancer in the French ESME cohort

N. Epaillard,A. Lusque, W. Jacot, A. Mailliez, T. Bachelot, M. Arnedos, V.C. Dieras, E.G.C. Brain,J-M. Ferrero, V. Massard, I. Desmoulins, M-A. Mouret,

ESMO Open（2023）

引用0浏览0引用

Corrigendum to "De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): characteristics and prognosis" [Eur J Cancer 158 (2021) 181-188]

T Gaillard, M Carton, A Mailliez, I Desmoulins,M A Mouret-Reynier, T Petit, M Leheurteur, V Dieras,J M Ferrero, L Uwer, S Guiu, A Gonc Alves,

European journal of cancer (Oxford, England : 1990) (2022): 311-312

引用0浏览0WOS引用

102P Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases: Characteristics and validation of prognostic models in a large real-life database

M. Carausu,M. Carton,A. Darlix,D. Pasquier, M. Leheurteur,M. Debled,M-A. Mouret-Reynier,A. Gonçalves, F. Dalenc,B. Verret, M. Campone,J-M. Ferrero,

Annals of Oncology（2021）

引用0浏览0引用

Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME)

D Dano, A Lardy-Cleaud,A Monneur,N Quenel-Tueux,C Levy,M-A Mouret-Reynier,B Coudert,A Mailliez,J-M Ferrero,S Guiu,M Campone,T de La Motte Rouge,

ESMO open（2021）

引用12浏览0WOS引用

Prognosis And Efficacy Of Frontline Treatment For Hr+Her2-Metastatic Breast Cancer Occurring In Gbrca1/2 Carriers

J-S. Frenel,A. Lusque, S. Delaloge,J-M. Ferrero, T. Bachelot, I. Desmoulins,C. Levy,J-C. Eymard,A. Goncalves, A. Patsouris,M. A. Mouret Reynier, M. Leheurteur,

ANNALS OF ONCOLOGY（2021）

引用0浏览0引用

Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort

T Grinda, A Antoine, W Jacot, C Blaye, P-H Cottu, V Diéras, F Dalenc,A Gonçalves, M Debled, A Patsouris,M-A Mouret-Reynier, A Mailliez,

ESMO openno. 3 (2021): 100114-100114

引用42浏览0WOS引用

43O Pertuzumab/trastuzumab in early stage HER2-positive breast cancer: 5-year and final analysis of the BERENICE trial

C. Dang,M.S. Ewer, S. Delaloge,J-M. Ferrero,R. Colomer,L. de la Cruz Merino, K. Dadswell, M. Verrill,D. Eiger, S. Sarkar,S. de Haas, E. Restuccia,

Annals of Oncology（2021）

引用4浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn